StockIQ.techRepligen Corporation (RGEN) Stock Analysis
Free AI-powered analysis and research for Repligen Corporation stock
Sector: Healthcare
RGEN snapshot
Data as of 4 Nov 2026 close. Updated daily.
Repligen Corporation scores 38/100 on StockIQ's model, which reads as negative signals overall. The price is above its 200-day average and at 79% of its 52-week range, up 21.6% over the past year. Latest reported figures show a profit margin of -1.5%, return on equity of -0.6% and revenue growth of +10.9%.
What is driving the score
- RSI Neutral: +5
- Flat Trend: +1
- MACD Bearish: -8
- Unprofitable (-1.5%): -15
- Strong Liquidity (9.88 Current Ratio): +8
- Negative ROE (-0.6%): -10
- High P/B (5.01): -5
- Strong Long-term Uptrend: +8
- Healthy Momentum (+21.6% over 1 year): +7
- Low Volume (0.4x): -3
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full RGEN report
Repligen Corporation (RGEN) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze RGEN Now →📰 Latest Update
5 must-read analyst questions from Repligen’s Q3 earnings call
Sat, October 31, 2026 at 2:35 PM UTC 2 min read
Repligen Corporation (RGEN) held its Q3 earnings call, addressing key analyst questions that highlighted the company's growth strategies and market position. The discussions focused on product demand, supply chain dynamics, and future revenue projections, which are crucial for investors assessing Repligen's potential for sustained growth. These insights may influence investor sentiment and stock performance as the company navigates a competitive bioprocessing landscape.